Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2008

View Archived Issues

Sangamo's new zinc finger protein transcription factor neuroprotective in spinal injury model

TMC-435350 well tolerated, with dose-dependent anti-HCV activity in phase II study

Med Discovery and Laborium Biopharma sign bioprocess development partnership

Idera and Merck & Co. extend research collaboration for Toll-like receptor agonists

Novel PGE2 receptor modulators emerge from Astellas R&D

New immunomodulatory agents disclosed in recent Novartis patent

Recent GSK patents disclose novel agents for tuberculosis

FDA accepts for review Labopharm's trazodone NDA for major depressive disorder

Phylogica to acquire all outstanding shares in subsidiary Dynamic Microbials

FDA extends review of Somaxon's NDA for insomnia drug Silenor by 3 months

Emisphere reports results from Novartis Pharma study of PTH-134 using Eligen technology

Covidien licenses worldwide rights to DepoMed's AcuForm drug delivery technology

King Pharmaceuticals signs definitive merger agreement with Alpharma

Transgene's TG-1042 meets primary endpoint in CBCL phase II trial

Recordati files MAA in Europe for silodosin for benign prostatic hyperplasia

Schering-Plough reports top-line results for Saphris in schizophrenia

Genzyme files sNDA for Clolar in adult myeloid leukemia

Preladenant meets primary endpoint in phase II dose-finding trial in PD

Advisory committee recommends FDA approval of febuxostat for gout

Aldose reductase inhibition lowers urinary albumin excretion in type 1 diabetes

Vascugel safe in phase I/II study in patients with arteriovenous access

Severity reduction of EAE with new sPLA2 inhibitor peptide

Lilly completes acquisition of ImClone Systems

Cephalon and ImmuPharma sign USD 15 million option agreement for Lupuzor for SLE

Phase I study data on ITMN-191 presented, ITMN-5489 introduced

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...